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Choroidal melanoma is a chemoresistant tumour which is fatal in
about 50% cases at 10 years and has a median survival of 5 to 7
months following the development of metastases (Ravio, 1977;
Albert et al, 1992; Bedikian et al, 1995). Although a high-risk
group can be defined by stage (tumour size) and microvascularity
(Foss et al, 1996), no adjuvant therapy is available for routine use.
Primary therapy is limited to enucleation or local irradiation
(Albert et al, 1992).
Treatment of metastatic choroidal melanoma with chemo-
therapy using regimens applied to skin melanoma has been largely
unsuccessful and has been based on the premise that because the
two tumours are derived from the same cell type, they may
respond similarly, despite the many genetic and phenotypic differ-
ences between them (Albert et al, 1996; Chana et al, 1998). While
occasional responses have been reported, there are few trial-based
data from which response rates can be obtained (Albert et al,
1992). One large series reported a response rate less than 1% for
systemic therapy, although chemoembolization of the liver using
cisplatin-based regimens was more effective, producing responses
in 36% of patients (Cantore et al, 1994; Bedikian et al, 1995). The
results of these studies suggest that at least some of these tumours
are partially sensitive to platinum-based therapy, although in
systemic combination with other drugs, cisplatin shows little
effect (Proebstle et al, 1996).
In a recent study of the chemosensitivity of uveal melanoma ex
vivo (Myatt et al, 1997), we used an ATP-based luminescence
assay (Hunter et al, 1993; Andreotti et al, 1995; Cree et al, 1996;
Kurbacher et al, 1998) to determine the sensitivity of primary
uveal melanoma to a variety of chemotherapeutic agents. We
observed variable sensitivity to treosulfan, cytosine arabinoside,
paclitaxel and doxorubicin and showed enhancement of the
response to treosulfan by cytosine arabinoside (Myatt et al, 1997).
Recently, a new derivative of cytosine arabinoside, gemcitabine,
has been shown to have greater effects on solid tumours (Plunkett
et al, 1995). Previous experience with gemcitabine in modulating
Cisplatin activity in ovarian cancer both clinically and in vitro was
encouraging (van Moorsel et al, 1997; Kurbacher et al, 1998). As a
corollary, we therefore decided to explore the use of the combina-
tion of treosulfan + gemcitabine further ex vivo by chemosensi-
tivity testing of primary uveal melanoma tumours.
MATERIALS AND METHODS
Melanomas
Material from 37 consecutive large primary intra-ocular
melanomas (Table 1) was obtained under sterile conditions from
fresh enucleation specimens removed consecutively at Moorfields
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All except two were previously untreated: the exceptions had
failed local ruthenium plaque or proton beam radiotherapy. Three
patients had had diagnostic choroidal biopsy preceding enucle-
ation. Enucleated eyes were examined externally for the presence
of extrascleral extension (present in four cases) or previous
surgery, and by transillumination using a fibre-optic light source to
locate the tumour. The eye was then oriented in a steel eye-cup and
sectioned posteriorly starting at the cornea to one side of the mid-
line continuing to the same side of the optic disc. The larger calotte
was placed immediately into 4% buffered formaldehyde for
histopathology, while the smaller calotte without the optic disk
was examined. The tumours ranged in size (largest tumour diam-
eter) from 7–23 mm, with a median of 12 mm. Ciliary body
involvement was present in four of 37 tumours, two of which
appeared to originate from the ciliary body, while the remainder
were restricted to the choroid. Tumour material was scraped from
the calotte and placed into 10 ml of Dulbecco’s Modified Eagle’s
Medium (DMEM) to which 100 U ml–1 penicillin and 100 mg ml–1
streptomycin had been added. The primary consideration was
always to obtain a histopathological diagnosis and in cases of
doubt, the bulk of the tumour was fixed for diagnostic use.
Histologically, 15 tumours were classified as spindle cell, 17 as
mixed and five as epithelioid tumours. The mitotic index varied
from 0–12 mitoses mm–2, with a median of 0.6 mitoses mm–2. A
further 10 tumours (nine choroidal, one ciliary body; five epithe-
lioid, three spindle, two mixed type; mitotic index 0–2.6) were
used in subsequent experiments to determine the effect of drug
sequence in combination experiments. Approval for use of
material not required for diagnosis was obtained from the
Moorfields Eye Hospital Ethics Committee.
ATP-based tumour chemosensitivity assay (ATP-TCA)
ATP-TCA was performed as previously described (Andreotti et al,
1995; Myatt et al, 1997). This assay is based on the linear relation-
ship between ATP content and biomass (Petty et al, 1995). Cells
were dissociated from melanoma tissue by incubation overnight at
37°C with 1.5 mg ml–1 collagenase type H (Sigma Chemical Co
Ltd., Poole, UK). The collagenase concentration was reduced to
0.75 mg ml–1 from tumour 36 onwards. Following dissociation, the
cells were washed in an antibiotic-containing serum-free complete
assay medium (CAM, DCS Innovative Diagnostik Systeme,
Hamburg, Germany) by centrifugation at 400 g for 10 min and
their viability checked by trypan blue exclusion. Cell viability
ranged from 50% to 95% (mean 85%). Ficoll-hypaque density
centrifugation (Lymphoprep, Nycomed UK Ltd, Birmingham,
UK) with two further washes was used in two cases to remove cell
debris. The cells were adjusted to 200 000 viable cells ml–1 in
CAM and 100 ml added to the wells of a 96-well polypropylene
microplate (Costar, High Wycombe, UK) to which doubling dilu-
tions of four drugs in triplicate wells (in 100-ml volumes) had been
added while the cells were being prepared. Test drug concentra-
tions (TDCs) are based on pharmacokinetic data adjusted to
provide good discrimination between tumours (Table 1) (Andreotti
et al, 1995). Combinations used two to three drugs added simulta-
neously unless otherwise specified. All drugs were left in the plate
for the duration of the culture period. One row was reserved for six
control wells with 100 ml CAM only (MO) and six wells to which
100 ml of a maximum inhibitor of cell survival (MI, DCS
Innovative Diagnostik Systeme) was added.
The plate was incubated for 6–7 days at 37°C with high humidity
in 5% CO2 and the cells observed every 2–3 days by microscopy to
check for infection or overgrowth. At the end of the incubation
period, ATP was extracted from the cells by addition of a detergent-
based extractant (TCER, DCS Innovative Diagnostik Systeme) and
50 ml from each well was added to 3.5 ml polystyrene tubes
(Sarstedt, Numbrecht, Germany) or white microtitre plates
(Dynatech Ltd, Billinghurst, UK), for estimation of ATP levels by
luminescence assay. The tubes were loaded into a Berthold LB953
luminometer (EG&G Berthold, Wildbad, Germany) set to inject
55 ml of luciferin–luciferase reagent (DCS Innovative Diagnostik
Systeme). Light output expressed as relative light units (RLU) was
used to determine the mean % inhibition of cell growth/survival in
triplicate wells at each drug concentration according to the
following equation: 1– ((Test – MI)/(MO – MI)) ´ 100.
For subsequent sequence experiments, plates were made up
with the first drug in 100-ml volumes down the plate as before and
cells added in 50 ml rather than 100 ml to allow later addition of
50 ml of the second drug (final concentration = 50% TDC) at
varying intervals. Cells were plated at 20 000 per well as before.
Cultures were stopped, and their ATP content and the degree of
inhibition were measured as usual. Six experiments were
performed with cytosine arabinoside + treosulfan, and four with
gemcitabine + treosulfan using primary uveal melanoma cells.
Data analysis
The results of each assay were analysed individually in an Excel
5.0 spreadsheet (Microsoft) allowing graphical representation of
the response (Figure 1) and collected in a database (Access 2.0,
Microsoft). Wells responsible for high variation in MO or test
results were examined and excluded as outliers or known errors
(e.g. pipetting, excessive cell clumping). For comparison of
responses between patients (Table 2), a simple logarithmic index
was derived by summing the percentage inhibition at each level of
TDC tested as Index = 700 – Sum[Inhibition3,13 … 200] (Hunter et al,
1993). An arbitrary level of 50% inhibition (Index < 350), IC50 and
IC90 were used to assess relative ex vivo sensitivity or resistance
(Table 3). Combination effects were assessed for independent and
combination effects using the method described by Poch et al
(1990).
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Table 1 Drug concentrations used in the assay and their clinically relevant
doses. For combinations, each drug was added at the TDCs to the same
wells. The dose correlation represents the standard dose from which
pharmacokinetic data were used to estimate the test drug concentration and
is given for information only
Drug name Test Drug Concentration (TDC) Drug dose
Correlation
m ml–1 mM
Cytosine arabinoside 2.4 9.87 I.V. 100 mg m–2
Doxorubicin 0.5 0.86 I.V. 60 mg m–2
Treosulfan 3 10.5 ORAL 1 g day–1
Vincristine 0.4 0.48 I.V. 1.5 mg m–2
Vinblastine 0.5 0.62 I.V. 6.0 mg m–2
Paclitaxel 6.8 7.96 I.V. 175 mg m–2
Gemcitabine 12.5 47.5 I.V. 1250 mg m–2
Mitoxantrone 0.3 0.58 I.V. 12 mg m–2RESULTS
Evaluable results were obtained from 31 of the 37 melanomas
tested, giving an evaluability rate of 84%. Six tumours were non-
evaluable: three had low MO values indicating death of most cells
(without drug present) and three yielded too few cells after disso-
ciation for assay (in one of these, the tumour was necrotic). No
infections were encountered before or during culture.
The single agent results (TCA Index) are detailed in Table 3A,
and the combination results in Table 3B to show the degree of
heterogeneity in responsiveness to individual drugs/combinations
between tumours. While most responded to treosulfan + cytosine
analogue, these cases showed considerable variability in their
response to other drugs. Table 2 gives a summary of the sensitivi-
ties using an arbitrary index of 350 as the cut-off below which the
agent/combination was said to be sensitive, together with the
number of cases in which the IC50 and IC90 fell within the range of
concentrations tested. In this study, the treosulfan sensitivity was
lower than previously observed (Myatt et al, 1997), although there
was a dose response in most cases evidenced by the IC50 and IC90
values. Figure 1A shows a typical result from one tumour for the
single agents and combination of treosulfan with cytosine arabi-
noside (Ara-C). This indicates modulation of the alkylating agent
response by Ara-C, as observed previously (Myatt et al, 1997).
Similar results were obtained with gemcitabine (Figure 1B),
although gemcitabine alone exhibited a slightly more pronounced
dose–response curve and showed less activity at low concentra-
tions. The combination–response curves (Poch et al, 1990, 1995)
suggest a greater effect of combining the two drugs than their inde-
pendent actions would predict at most concentrations, particularly
in the mid-range (Figure 1C and 1D).
While most tumours showed a response to treosulfan which
could be modulated by cytosine analogues, there was consider-
able variation between individuals in the response to other single
agents (Table 3). There was no relationship between sensitivity
index for any of the drugs listed and mitotic rate, tumour size or
cell type. Many tumours showed a response to cytosine arabi-
noside (43%) or gemcitabine (30%) as single agent. However,
these drugs never induce 100% cell kill when present alone.
Sensitivity to anthracyclines was observed in 7% of cases tested
with doxorubicin and 11% tested with mitoxantrone. There was
some indication of a lack of cross-resistance between these two
Chemotherapy for choroidal melanoma 1489
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Figure 1 Example ATP-TCA results for the combination of treosulfan with (A) cytosine arabinoside (case 15) and (B) gemcitabine (case 30) with combination
effect graphs (Poch et al, 1990) for (C) treosulfan + cytosine arabinoside and (D) treosulfan + gemcitabine. In both sets of results, there is some sensitivity to
both cytosine analogues at all concentrations tested, but this never reaches 100% inhibition. Treosulfan sensitivity is poor at most concentrations, but there is
greater than 90% inhibition at high concentrations. However, in both cases, the combination is much more effective. TDC = test drug concentrationanthracyclines with generally greater sensitivity to mitoxantrone.
Fourteen per cent of cases showed sensitivity to paclitaxel, but
there were no responses to vinca alkaloids (vincristine or vinblas-
tine). The combination of paclitaxel with doxorubicin showed
activity in 31%, while mitoxantrone + paclitaxel was effective in
33%.
Treosulfan + cytosine arabinoside was the best of the double-
agent combinations, with 86% of patients showing sensitivity. The
combination of treosulfan with gemcitabine showed similar effi-
cacy in 70% cases. While the highest sensitivity was seen for the
combination of treosulfan + paclitaxel + cytosine arabinoside
(92%), in general paclitaxel added little to the sensitivity of the
combination (Figure 2A). However, in occasional patients with
limited treosulfan sensitivity and some paclitaxel sensitivity, pacli-
taxel addition does improve the response (Figure 2B).
Schedule experiments combining treosulfan at different times
with cytosine arabinoside or gemcitabine are shown in Figure 3.
These experiments were conducted with 50% TDC concentrations
of cytosine arabinoside or gemcitabine and show simultaneous
addition to be most effective. Prior addition of gemcitabine or
cytosine arabinoside before treosulfan abrogated the effect of the
alkylating agent and in this sequence the combination failed to
produce 100% inhibition.
DISCUSSION
In the UK, rare tumours (i.e. those outside the top 10 for inci-
dence) account for 25% of deaths from cancer (Thames Cancer
Registry, 1995). Choroidal melanoma is rare with an age-standard-
ized incidence of 0.4 to 1.2 cases per 100 000 within Europe (Foss
and Dolin, 1996). Consequently, clinical trials are difficult and
rarely performed as funding bodies, whether industrial or chari-
table, prefer to concentrate resources on more common tumours.
Yet these patients need treatment. Chemosensitivity testing has a
poor reputation following a long history of technical problems.
However modern methods offer a way of testing new drugs and
regimens in rare tumours which could not be contemplated in the
clinical setting. ATP-based methods have theoretical advantages
of sensitivity and reproducibility over other methods (Petty et al,
1995; Cree and Kurbacher, 1997). The ATP-TCA overcomes most
of the difficulties which have beset chemosensitivity testing and
shows considerable promise as a way of individualizing
chemotherapy (Cree and Kurbacher, 1997). Correlation of sensi-
tivity in the ATP-TCA with clinical response is comparable with
bacteriological or oestrogen receptor testing at 75–80% (Andreotti
et al, 1995; Cree et al, 1996; Cree and Kurbacher, 1997). For
choroidal melanoma, our evaluability rate has improved from 71%
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Table 2 Summary of results using an arbitrary threshold for sensitivity of Index < 350, and the number of cases in which the IC50
and IC90 fell within the range of concentrations tested (3.13–200% TDC). Treosulfan is the most active alkylating agent tested and
the combinations with cytosine arabinoside or gemcitabine are effective in most tumours tested. The median and range (in
brackets) for each parameter in terms of TDC% are shown below, where these fall within the concentration range tested. na = not
achieved.
Drug Sensitivity index IC50 IC90
Cytosine arabinosidea 12/28 (43%) 19/29 (66%) 1/29(3%)
387 (63–875) 5 (4–60) na
Doxorubicin 2/27 (7%) 10/23 (43%) 0/23 (0%)
494 (307–1309) 92 (9–159) na
Treosulfan 2/31 (6%) 18/31 (58%) 6/31 (19%)
491 (191–1003) 105 (3–163) 21 (14–53)
Vincristine/vinblastine 0/14 (0%) 0/14 (0%) 0/14 (0%)
682 (482–1011) na na
Paclitaxel 4/29 (14%) 13/33 (39%) 1/33 (3%)
525 (189–816) 109 (3–186) 199
Gemcitabine 6/20 (30%) 8/20 (40%) 0/20 (0%)
480 (237–918) 85 (4–143) na
Mitoxantrone 1/9 (11%) 5/9 (56%) 0/9 (0%)
384 (258–514) 112 (98–157) na
Mitoxantrone + Paclitaxel 3/9 (33%) 9/9 (100%) 3/9 (33%)
373 (258–485) 134 (101–170) 32 (22–40)
Doxorubicin + Paclitaxel 8/26 (31%) 20/26 (77%) 9/26 (34%)
400 (233–657) 125 (3–180) 30 (22–39)
Treosulfan + Ara C 25/29 (86%) 27/29 (93%) 20/29 (69%)
214 (28–611) 3 (3–175) 41 (6–121)
Treosulfan + Gemcitabine 16/23 (70%) 22/23 (96%) 18/23 (78%)
306 (61–698) 104 (3–161) 28 (6–72)
Treosulfan + Doxorubicin 1/8 (13%) 7/8 (88%) 3/8 (38%)
433 (178–625) 107 (3–158) 65 (28–73)
Treosulfan + Paclitaxel 8/17 (47%) 16/17 (94%) 13/17 (76%)
353 (131–567) 126 (3–175) 32 (20–88)
Treosulfan + Paclitaxel + Ara C 11/12 (92%) 11/11 (100%) 11/11 (100%)
148 (36–351) 3 (3–134) 43 (6–73)
Treosulfan + Paclitaxel + Gemcitabine 9/11 (82%) 11/11 (100%) 10/11 (91%)
286 (189–456) 105 (3–194) 33 (24–43)
a100% melanoma cell kill not achieved.Chemotherapy for choroidal melanoma 1491
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(B)
Number Mitoxantrone Doxorubicin Treosulfan Treosulfan Treosulfan Treosulfan Treosulfan Treosulfan
+ Paclitaxel + Pacltaxel + Ara C + Gemcitabine + Doxorubicin + Paclitaxel + Paclitaxel + Paclitaxel
+ Ara C + Gemcitabine
1n d n d n d n dn d n d n d n d
3 nd 334 250 nd nd nd nd nd
4 nd 357 464 nd nd nd nd nd
5 nd 284 611 nd nd nd nd nd
7 nd 462 206 nd nd nd nd nd
8 nd 403 582 nd nd nd nd nd
9 nd 347 148 nd nd nd nd nd
11 nd 233 73 210 178 131 119 nd
12 nd 399 28 61 461 375 36 nd
13 nd 401 99 100 625 302 68 nd
14 nd 293 90 130 nd nd 54 nd
15 nd 513 191 228 nd nd 173 nd
16 nd 483 242 387 543 334 242 nd
17 nd 424 513 374 406 368 302 nd
18 nd 441 98 86 nd nd 123 nd
19 nd 283 214 315 406 202 257 nd
20 nd 657 312 378 496 567 351 nd
21 nd nd 203 nd nd nd 118 nd
23 nd 367 257 431 391 291 180 nd
24 nd nd 303 698 nd nd nd nd
26 nd nd 260 367 nd nd nd 402
27 384 640 275 343 nd 555 nd 319
28 339 487 125 237 nd 353 nd 249
29 442 459 140 218 nd 392 nd 198
30 361 400 276 312 nd 461 nd 286
31 373 311 113 273 nd 284 nd 189
33 258 304 160 339 nd 336 nd 336
34 nd nd nd 245 nd nd nd 228
35 485 565 281 389 nd 463 nd 456
36 337 514 251 306 nd 470 nd 311
37 426 263 129 254 nd 222 nd 221
Table 3 Results of testing for each tumour expressed as a simple summary index of inhibition across the range of
concentrations tested for (A) single agents and (B) Paclitaxel and combinations. Low values indicate considerable inhibition,
while higher values indicate resistance. Values greater than 700 indicate growth greater than control wells, which is likely to be
artefactual and simply reflects resistance. nd = not done.
(A)
Number Cytosine Doxorubicin Treosulfan Vincristine Paclitaxel Gemcitabine Mitoxantrone
arabinoside Vinblastinea
1 685 465 539 671 465 nd nd
3 641 429 510 682 220 nd nd
4 752 606 720 604 393 nd nd
5 820 307 739 725 407 nd nd
7 248 449 380 nd 410 nd nd
8 653 539 566 482 525 nd nd
9 274 633 402 nd 476 nd nd
11 181 320 600 592 189 273 nd
12 63 453 491 nd 464 237 nd
13 196 501 507 759 500 284 nd
14 180 337 462 nd 478 nd nd
15 367 541 420 nd 556 nd nd
16 423 615 364 633 580 529 nd
17 670 464 623 613 581 605 nd
18 183 382 191 nd 582 nd nd
19 379 513 449 767 329 587 nd
20 453 638 521 891 816 918 nd
21 480 nd 397 nd 327 nd nd
23 396 409 456 726 569 589 nd
24 627 781 1003 1011 nd 678 nd
26 nd nd 389 nd 607 460 nd
27 498 654 472 nd 653 501 384
28 nd nd 345 nd 530 429 339
29 320 494 446 nd 611 638 442
30 601 475 520 nd 594 515 361
31 173 529 400 nd 442 328 373
33 331 611 522 nd 541 456 258
34 nd nd 633 nd nd 330 nd
35 875 1309 520 nd 677 576 485
36 261 476 573 nd 640 414 406
37 311 483 429 nd 439 324 514
aVinblastine used from 97M011 onwards.in the first 28 cases tested (Myatt et al, 1997) to 86% in this series
(the current series includes four of the first series tumours in which
combinations were tested). The improvement probably reflects the
gentler dissociation and cell handling used in comparison with our
initial practice (Myatt et al, 1997).
Our previous (Myatt et al, 1997) and current results confirm the
chemoresistance of choioidal melanoma, but also suggest that
there are options for improvement of response rates. The current
study shows few differences from our previous study. Although
the sensitivity of the melanomas to treosulfan was reduced (Table
2), examination of the individual data shows that most tumours
(Table 3) did exhibit some sensitivity to this agent, which remains
the best of the alkylating agents we have tried in the assay. We
have previously shown that these tumours are relatively unrespon-
sive to temozolomide (Myatt et al, 1997), a drug closely related to
dacarbazine (DTIC) which forms the mainstay of treatment for
cutaneous melanoma, but has poor results against uveal melanoma
(Bedikian et al, 1995). Results for other agents were similar to
those obtained previously, with confirmation of some sensitivity of
uveal melanoma to paclitaxel, cytosine arabinoside and anthracy-
clines. As before, vinca alkaloids showed little effect.
There is heterogeneity of chemosensitivity (Table 2), as we have
previously observed in many tumour types (Hunter et al, 1993;
Andreotti et al, 1995), but on the basis of these results many previ-
ously untreated uveal melanomas are likely to respond to the
combination of treosulfan with cytosine analogues. However, it
should be noted that we have tested primary tumour material, not
metastases, and it is possible that these may show differences in
chemosensitivity. For clinical use, we have chosen to pursue the
combination of gemcitabine + treosulfan, as the pharmacokinetics
and activity of gemcitabine in solid tumours are superior to cyto-
sine arabinoside. Preliminary clinical use of this combination in 18
heavily pre-treated patients with recurrent ovarian or breast carci-
noma based on sensitivity in ATP-TCA is encouraging (data not
shown) with a good safety profile and we believe that it may have
wider applicability. A phase I/II trial of treosulfan + gemcitabine
in metastatic uveal melanoma is now in progress, and we have
commenced a phase II trial of assay-directed chemotherapy in
melanoma patients with accessible disease, based on this data and
studies of skin melanoma (Neale et al, unpublished data).
The differences we have observed between gemcitabine and
cytosine arabinoside are interesting. Although these agents show
1492 MH Neale et al
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Figure 2 Examples showing addition of paclitaxel to the combination of treosulfan + gemcitabine. In case 28 (A) there is no effect, while in case 31 (B) a small
effect is observed. TDC = test drug concentration
100
80
60
40
20
Treo (0 h) + Cyt A (0 h)
A
%
 
I
n
h
i
b
i
t
i
o
n
3.13
TDC %
25
0
6.25 12.5 50 100 200
Treo (0 h) + Cyt A (6 h)
Treo (0 h) + Cyt A (24 h) x Cyt A (0 h) + Treo (24 h)
100
80
60
40
20
Treo (0 h) + Gem (0 h)
B
%
 
I
n
h
i
b
i
t
i
o
n
3.13
% TDC
25
0
6.25 12.5 50 100 200
Treo (0 h) + Gem (6 h)
Treo (0 h) + Gem (24 h) Gem (0 h) + Treo (24 h) x
Figure 3 Sequential studies with (A) cytosine arabinoside and (B) gemcitabine in combination with treosulfan. When either cytosine analogue is given before
the treosulfan, the combination fails to acheive 100% inhibition. In both cases, best inhibition is achieved by concomitant administration of the two drugs. TDC =
test drug concentrationclose cross-sensitivity, and both are cytosine analogues, there are
major differences in their pharmacology (Peters et al, 1996).
Several biochemical explanations are possible, but there is little
doubt that gemcitabine is a useful drug in combination with alkyl-
ating agents in particular (Peters et al, 1996; Iwasaki et al, 1997;
Bruckner HW, personal communication). The explanation for the
apparent modulation of treosulfan sensitivity observed with both
drugs may be due to inhibition of DNA repair of alkylating agent-
induced cross-links, to direct incorporation of the analogues into
DNA, to changes in dNTP pools (Peters et al, 1996; Iwasaki et al,
1997), or to a combination of several of these mechanisms. Further
studies using assays of DNA repair and measurement of dNTP
pools are required, but our results show clear evidence of synergy
between the alkylating agent and cytosine analogue in primary
uveal melanoma for both drugs given simultaneously.
Analysis of the single agent responses confirms our previous
data showing a lack of activity of vinca alkaloids in this tumour, but
some activity for paclitaxel. We had hoped that addition 
of paclitaxel to the combination of treosulfan with cytosine
analogues might further improve responses, but in general the data
do not support addition of this agent which would also add consid-
erable toxicity. Occasional patients respond better to paclitaxel +
anthracyclines than treosulfan + cytosine analogues. This was
observed in three of the early cases studied (Table 3B) and it is clear
from our data that there may be a role for paclitaxel and anthracy-
clines in patients refractory to treosulfan + cytosine analogue.
Routine chemosensitivity testing to individualize testing is prob-
ably not appropriate in these patients, though it is certainly feasible,
and current phase III trials of the technology may alter this view.
In this study, the ATP-TCA has shown itself able to predict
combinations suitable for use in rare solid tumours in which there
is no prospect of doing the number of phase II trials which would
be required using current empirical methods. As the number of
agents available continues to grow, the need for some form of
preclinical planning of phase II trials becomes more apparent. The
method used here allows large numbers of mechanistically logical
permutations to be tested with material from small numbers of
patients with potential benefits in terms of development time and
expense.
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